Shareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with Biosynex

MILWAUKEE, April 20, 2023 /PRNewswire/ -- Ademi LLP is investigating Chembio (NASDAQ: CEMI) for possible breaches of fiduciary duty and other violations of law in its transaction with Biosynex. 

Click here to learn how to join the action https://www.ademilaw.com/case/chembio-diagnostics-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Chembio's shareholders are expected to receive only $0.45 per share, in an all-cash transaction valued at $17.2 million. The transaction agreement unreasonably limits competing bids for Chembio by imposing a significant penalty if Chembio accepts a superior bid. Chembio insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Chembio's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Chembio.

If you own Chembio common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/chembio-diagnostics-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-chembio-diagnostics-inc-has-obtained-a-fair-price-in-its-transaction-with-biosynex-301802924.html

SOURCE Ademi LLP